{{Drugbox
| Watchedfields = changed
| verifiedrevid = 462261036
| IUPAC_name = 5,5-Dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione
| image = Nilutamide.svg

<!--Clinical data-->
| pronounce = nye-LOO-tah-mide<ref name="LiverTox">https://livertox.nlm.nih.gov/Nilutamide.htm</ref>
| tradename = Nilandron, Anandron
| Drugs.com = {{drugs.com|monograph|nilutamide}}
| MedlinePlus = a697044
| pregnancy_US = C
| pregnancy_US_comment = <ref>https://www.drugs.com/pregnancy/nilutamide.html</ref>
| legal_status = Rx-only
| routes_of_administration = [[Oral administration|Oral]]<ref name="PerryDoll2012" />
| class = [[Nonsteroidal antiandrogen]]

<!--Pharmacokinetic data-->
| bioavailability = Good<ref name="PerryDoll2012">{{cite book|author1=Michael C. Perry|author2=Donald C. Doll|author3=Carl E. Freter|title=Perry's The Chemotherapy Source Book|url=https://books.google.com/books?id=My3SjQTguyYC&pg=PA711|date=30 July 2012|publisher=Lippincott Williams & Wilkins|isbn=978-1-4698-0343-2|pages=711–}}</ref>
| protein_bound = 80–84%<ref name="LemkeWilliams2012">{{cite book|author1=Thomas L. Lemke|author2=David A. Williams|title=Foye's Principles of Medicinal Chemistry|url=https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA1373|date=24 January 2012|publisher=Lippincott Williams & Wilkins|isbn=978-1-60913-345-0|pages=1373–}}</ref>
| metabolism = [[Liver]]: [[CYP2C19]], [[Flavin-containing monooxygenase|FMO]]<ref name="PerryDoll2012" /><ref name="LemkeWilliams2012" />
| metabolites = At least 5, some active<ref name="LemkeWilliams2012" /><ref name="ChabnerLongo2010" />
| elimination_half-life = 23–87 hours (mean 56 hours, or about 2 days)<ref name="CRAIGFurr2010">{{cite book|author1=JORDAN V. CRAIG|author2=B.J.A. Furr|title=Hormone Therapy in Breast and Prostate Cancer|url=https://books.google.com/books?id=dM0uvBnxiN0C&pg=PA350|date=5 February 2010|publisher=Springer Science & Business Media|isbn=978-1-59259-152-7|pages=347, 350, 356|quote=Although the t1/2 of nilutamide is  h (mean 56 h) (39), suggesting that once-daily dosing would be appropriate, a three times per day regimen has been employed in most clinical trials.}}</ref>
| excretion = [[Urine]] (62%);<br />[[Feces]] (<10%)<ref name="PerryDoll2012" /><ref name="LemkeWilliams2012" />

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 63612-50-0
| ATC_prefix = L02
| ATC_suffix = BB02
| ATC_supplemental =  
| PubChem = 4493
| IUPHAR_ligand = 2864
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00665
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4337
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 51G6I8B902
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00965
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 7573
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1274

<!--Chemical data-->
| C=12 | H=10 | F=3 | N=3 | O=4
| molecular_weight = 317.221 g/mol
| smiles = O=C2N(c1ccc([N+]([O-])=O)c(c1)C(F)(F)F)C(=O)C(N2)(C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = XWXYUMMDTVBTOU-UHFFFAOYSA-N
| synonyms = RU-23908
}}

'''Nilutamide''' (brand names '''Nilandron''', '''Anandron''') is a [[nonsteroidal antiandrogen]] (NSAA) used in the treatment of [[metastatic]] [[prostate cancer]].<ref name="GanellinTriggle1996">{{cite book|author1=C.R. Ganellin|author2=David J. Triggle|title=Dictionary of Pharmacological Agents|url=https://books.google.com/books?id=A0THacd46ZsC&pg=PA1431|date=21 November 1996|publisher=CRC Press|isbn=978-0-412-46630-4|pages=1431–}}</ref><ref name="MortonMorton1999">{{cite book|author1=Dr. Ian Morton|author2=I.K. Morton|author3=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=mqaOMOtk61IC&pg=PA199|date=31 October 1999|publisher=Springer Science & Business Media|isbn=978-0-7514-0499-9|pages=199–}}</ref><ref name="DenisGriffiths1999">{{cite book|author1=Louis J Denis|author2=Keith Griffiths|author3=Amir V Kaisary |author4=Gerald P Murphy |title=Textbook of Prostate Cancer: Pathology, Diagnosis and Treatment: Pathology, Diagnosis and Treatment|url=https://books.google.com/books?id=GreZlojD-tYC&pg=PA280|date=1 March 1999|publisher=CRC Press|isbn=978-1-85317-422-3|pages=280–}}</ref> It acts as a [[binding selectivity|selective]] [[receptor antagonist|antagonist]] of the [[androgen receptor]] (AR). Because most prostate cancer cells rely on [[androgen]]s like [[testosterone]] and [[dihydrotestosterone]] (DHT) for growth and survival, nilutamide can slow the progression of the disease and extend life in men with prostate cancer.<ref name="Denis2012-1" />

Nilutamide shows unique and unfavorable [[tolerability]] and [[toxicity]] profiles, most importantly a high incidence of [[interstitial pneumonitis]] (which can progress to [[pulmonary fibrosis]], a potentially fatal condition),<ref name="BoarderNewby2010">{{cite book|author1=Michael Boarder|author2=David Newby|author3=Phyllis Navti|title=Pharmacology for Pharmacy and the Health Sciences: A Patient-centred Approach|url=https://books.google.com/books?id=KVicAQAAQBAJ&pg=PA632|date=25 March 2010|publisher=OUP Oxford|isbn=978-0-19-955982-4|pages=632–}}</ref> and this has limited its clinical use.<ref name="DenisGriffiths1999" /><ref name="DeVitaLawrence2016">{{cite book|author1=Vincent T. DeVita|author2=Theodore S. Lawrence|author3=Steven A. Rosenberg|title=Prostate and Other Genitourinary Cancers: Cancer: Principles & Practice of Oncology|url=https://books.google.com/books?id=Bf3DCwAAQBAJ&pg=PT1006|date=18 March 2016|publisher=Wolters Kluwer Health|isbn=978-1-4963-5421-1|pages=1006–}}</ref><ref name="Chang2005" /> From a [[drug safety|safety]] standpoint, [[bicalutamide]] is clinically preferred not only over nilutamide (due primarily to its risk of interstitial pneumonitis) but also [[flutamide]] (due to its high risk of [[hepatotoxicity]]) in choice of NSAA.<ref name="Gulley2011" />

==Medical uses==

===Prostate cancer===
Nilutamide is used in prostate cancer in combination with a [[gonadotropin-releasing hormone]] (GnRH) [[gonadotropin-releasing hormone analogue|analogue]] at a dosage of 300&nbsp;mg/day (150&nbsp;mg twice daily) for the first 4 weeks of treatment, and 150&nbsp;mg/day thereafter.<ref name="Chang2005"/><ref name="Upfal2006">{{cite book|author=Jonathan Upfal|title=The Australian Drug Guide: Every Person's Guide to Prescription and Over-the-counter Medicines, Street Drugs, Vaccines, Vitamins and Minerals...|url=https://books.google.com/books?id=7O9kiqN2q2YC&pg=PA283|year=2006|publisher=Black Inc.|isbn=978-1-86395-174-6|pages=283–}}</ref> It is not indicated as a [[monotherapy]] in prostate cancer.<ref name="Chang2005" />

===Transgender hormone therapy===
Nilutamide has been researched and used as a component of [[hormone replacement therapy (male-to-female)|hormone replacement therapy]] in [[transgender women]].<ref name="Denis2012-1"/><ref name="KreukelsSteensma2013">{{cite book|author1=Baudewijntje P.C. Kreukels|author2=Thomas D. Steensma|author3=Annelou L.C. de Vries|title=Gender Dysphoria and Disorders of Sex Development: Progress in Care and Knowledge|url=https://books.google.com/books?id=YQ5GAAAAQBAJ&pg=PA280|date=1 July 2013|publisher=Springer Science & Business Media|isbn=978-1-4614-7441-8|pages=280–}}</ref> It has been assessed in at least five small [[clinical trial|clinical studies]] for this purpose in treatment-naive subjects.<ref name="KreukelsSteensma2013" /><ref name="AsschemanGooren1989">{{cite journal|last1=Asscheman|first1=H.|last2=Gooren|first2=I. J. G.|last3=Peereboom-Wynia|first3=J. D. R.|title=Reduction in undesired sexual hair growth with Anandron in male-to-female transsexuals-experiences with a novel androgen receptor blocker|journal=Clinical and Experimental Dermatology|volume=14|issue=5|year=1989|pages=361–363|issn=0307-6938|doi=10.1111/j.1365-2230.1989.tb02585.x|pmid=2612040}}</ref><ref name="Raode Voogt1988">{{cite journal|last1=Rao|first1=B.Ramanath|last2=de Voogt|first2=H.J.|last3=Geldof|first3=A.A.|last4=Gooren|first4=L.J.G.|last5=Bouman|first5=F.G.|title=Merits and considerations in the use of anti-androgen|journal=Journal of Steroid Biochemistry|volume=31|issue=4|year=1988|pages=731–737|issn=0022-4731|doi=10.1016/0022-4731(88)90024-6|pmid=3143862}}</ref><ref name="van KemenadeCohen-Kettenis1989">{{cite journal|last1=van Kemenade|first1=Johannes F. L. M.|last2=Cohen-Kettenis|first2=Peggy T.|last3=Cohen|first3=Leo|last4=Gooren|first4=Louis J. G.|title=Effects of the pure antiandrogen RU 23.903 (anandron) on sexuality, aggression, and mood in male-to-female transsexuals|journal=Archives of Sexual Behavior|volume=18|issue=3|year=1989|pages=217–228|issn=0004-0002|doi=10.1007/BF01543196|pmid=2751416}}</ref><ref name="GoorenSpinder1987">{{cite journal|last1=Gooren|first1=L.|last2=Spinder|first2=T.|last3=Spijkstra|first3=J. J.|last4=Van Kessel|first4=H.|last5=Smals|first5=A.|last6=Rao|first6=B. R.|last7=Hoogslag|first7=M.|title=Sex Steroids and Pulsatile Luteinizing Hormone Release in Men. Studies in Estrogen-Treated Agonadal Subjects and Eugonadal Subjects Treated with a Novel Nonsteroidal Antiandrogen|journal=The Journal of Clinical Endocrinology & Metabolism|volume=64|issue=4|year=1987|pages=763–770|issn=0021-972X|doi=10.1210/jcem-64-4-763|pmid=3102546}}</ref><ref name="De VoogtRao1987">{{cite journal|last1=De Voogt|first1=H. J.|last2=Rao|first2=B. R.|last3=Geldof|first3=A. A.|last4=Gooren|first4=L. J. G.|last5=Bouman|first5=F. G.|title=Androgen action blockade does not result in reduction in size but changes histology of the normal human prostate|journal=The Prostate|volume=11|issue=4|year=1987|pages=305–311|issn=0270-4137|doi=10.1002/pros.2990110403|pmid=2960959}}</ref> In these studies, nilutamide monotherapy at a dosage of 300&nbsp;mg/day, induced observable signs of clinical [[feminization (biology)|feminization]] in young transgender women (age range 19–33 years) within 8 weeks,<ref name="Raode Voogt1988" /> including [[breast development]], decreased [[body hair]] (though not [[facial hair]]),<ref name="AsschemanGooren1989" /> decreased [[morning erection]]s and [[sex drive]],<ref name="van KemenadeCohen-Kettenis1989" /> and positive psychological and emotional changes.<ref name="van KemenadeCohen-Kettenis1989" /><ref name="Cohen-KettenisGooren1993">{{cite journal|last1=Cohen-Kettenis|first1=Peggy T.|last2=Gooren|first2=Louis J.G.|title=The Influence of Hormone Treatment on Psychological Functioning of Transsexuals|journal=Journal of Psychology & Human Sexuality|volume=5|issue=4|year=1993|pages=55–67|issn=0890-7064|doi=10.1300/J056v05n04_04}}</ref> Signs of breast development occurred in all subjects within 6 weeks and were associated with increased [[nipple sensitivity]],<ref name="De VoogtRao1987" /><ref name="Raode Voogt1988" /><ref name="van KemenadeCohen-Kettenis1989" /> and along with decreased hair growth, were the earliest sign of feminization.<ref name="Raode Voogt1988" />

Nilutamide did not change the size of the [[prostate gland]] (which is the same as with high-dosage [[cyproterone acetate]] and [[ethinylestradiol]] treatment for as long as 18 months), but was found to alter its [[histology]], including increased [[stromal tissue]] with a significant reduction in [[acinus|acini]] and atrophic [[epithelial cell]]s, indicating glandular [[atrophy]].<ref name="GoorenSpinder1987" /><ref name="De VoogtRao1987" /> In addition, readily apparent histological changes were observed in the [[testicle|testes]], including a reduction in [[seminiferous tubule|tubular]] and [[interstitial cell]]s.<ref name="GoorenSpinder1987" />

Nilutamide was found to more than double [[luteinizing hormone]] (LH) and [[testosterone]] levels and to triple [[estradiol]] levels.<ref name="AsschemanGooren1989" /><ref name="Raode Voogt1988" /><ref name="GoorenSpinder1987" /> In contrast, [[follicle-stimulating hormone]] levels remained unchanged.<ref name="Raode Voogt1988" /><ref name="GoorenSpinder1987" /> A slight but significant increase in [[prolactin]] levels was observed, and levels of [[sex hormone-binding globulin]] increased as well.<ref name="Raode Voogt1988" /><ref name="GoorenSpinder1987" /> The addition of ethinylestradiol to nilutamide therapy after 8 weeks abolished the increase in LH, testosterone, and estradiol levels and dramatically suppressed testosterone levels, into the [[castration|castrate]] range.<ref name="AsschemanGooren1989" /><ref name="Raode Voogt1988" /> Both nilutamide alone and the combination of nilutamide and [[estrogen]] were regarded as resulting in effective and favorable antiandrogen action and feminization in transgender women.<ref name="AsschemanGooren1989" /><ref name="Raode Voogt1988" />

===Acne and seborrhea===
Nilutamide has been assessed in the treatment of [[acne]] and [[seborrhea]] in women in at least one small clinical study.<ref name="pmid2744186">{{cite journal | vauthors = Couzinet B, Thomas G, Thalabard JC, Brailly S, Schaison G | title = Effects of a pure antiandrogen on gonadotropin secretion in normal women and in polycystic ovarian disease | journal = Fertil. Steril. | volume = 52 | issue = 1 | pages = 42–50 | year = 1989 | pmid = 2744186 | doi = | url = }}</ref><ref name="pmid2462132">{{cite journal | vauthors = Namer M | title = Clinical applications of antiandrogens | journal = J. Steroid Biochem. | volume = 31 | issue = 4B | pages = 719–29 | year = 1988 | pmid = 2462132 | doi = | url = }}</ref> The dosage used was 200&nbsp;mg/day, and in the study, "seborrhea and acne decreased markedly within the first month and practically disappeared after 2 months of [nilutamide] treatment."<ref name="pmid2744186" /><ref name="pmid2462132" />

==Side effects==
General [[side effect]]s of NSAAs, including nilutamide, include [[gynecomastia]] (40–80%), [[mastodynia|breast pain/tenderness]], [[hot flash]]es (67%), [[depression (mood)|depression]], [[fatigue (medical)|fatigue]], [[sexual dysfunction]] (including loss of [[libido]] and [[erectile dysfunction]]), decreased [[muscle]] mass, and decreased [[bone]] mass with an associated increase in [[bone fracture|fracture]]s.<ref name="Dart2004">{{cite book|author=Richard C. Dart|title=Medical Toxicology|url=https://books.google.com/books?id=BfdighlyGiwC&pg=PA521|year=2004|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-2845-4|pages=521–}}</ref><ref name="MDMD2008">{{cite book|author1=Lisa M DeAngelis MD|author2=Jerome B Posner MD|title=Neurologic Complications of Cancer|url=https://books.google.com/books?id=mpZ8Dp2KdHMC&pg=PA479|date=12 September 2008|publisher=Oxford University Press, USA|isbn=978-0-19-971055-3|pages=479–}}</ref><ref name="Lehne2013">{{cite book|author=Richard A. Lehne|title=Pharmacology for Nursing Care|url=https://books.google.com/books?id=_4SwO2dHcAIC&pg=PA1297|year=2013|publisher=Elsevier Health Sciences|isbn=1-4377-3582-7|pages=1297–}}</ref> Also, [[nausea]] (24–27%), [[vomiting]], [[constipation]] (20%), and [[insomnia]] (16%) may occur with nilutamide.

Relative to other NSAAs, nilutamide has been uniquely associated with mild and reversible [[visual disturbance]]s (31–58%) including delayed ocular adaptation to darkness and impaired [[color vision]],<ref name="Becker2001">{{cite book|author=Kenneth L. Becker|title=Principles and Practice of Endocrinology and Metabolism|url=https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1196|year=2001|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-1750-2|pages=1196–}}</ref> a [[disulfiram]]-like<ref name="Dart2004" /> [[drinking alcohol|alcohol]] [[drug intolerance|intolerance]] (19%), [[interstitial pneumonitis]] (0.77–2.4%)<ref name="Gulley2011">{{cite book|author=James Leonard Gulley|title=Prostate Cancer|url=https://books.google.com/books?id=WJkjgbRJe3EC&pg=PT81|year=2011|publisher=Demos Medical Publishing|isbn=978-1-935281-91-7|pages=81–}}</ref><ref name="CamusIII2010">{{cite book|author1=Phillipe Camus|author2=Edward C Rosenow III|title=Drug-induced and Iatrogenic Respiratory Disease|url=https://books.google.com/books?id=QlJsBgAAQBAJ&pg=PA235|date=29 October 2010|publisher=CRC Press|isbn=978-1-4441-2869-7|pages=235–}}</ref><ref name="Held-Warmkessel2006">{{cite book|author=Jeanne Held-Warmkessel|title=Contemporary Issues in Prostate Cancer: A Nursing Perspective|url=https://books.google.com/books?id=dZe4ZSVDdBsC&pg=PA257|year=2006|publisher=Jones & Bartlett Learning|isbn=978-0-7637-3075-8|pages=257–}}</ref> (which can result in [[dyspnea]] (1%) as a secondary effect and can progress to [[pulmonary fibrosis]]),<ref name="WeinKavoussi2011">{{cite book|author1=Alan J. Wein|author2=Louis R. Kavoussi|author3=Andrew C. Novick |author4=Alan W. Partin |author5=Craig A. Peters |title=Campbell-Walsh Urology: Expert Consult Premium Edition: Enhanced Online Features and Print, 4-Volume Set|url=https://books.google.com/books?id=fu3BBwAAQBAJ&pg=PA2939|date=25 August 2011|publisher=Elsevier Health Sciences|isbn=978-1-4160-6911-9|pages=2939–}}</ref> and [[hepatitis]] (1%), and has a higher incidence of nausea and vomiting compared to other NSAAs.<ref name="DenisGriffiths1999" /><ref name="Chang2005">{{cite book|author=Chawnshang Chang|title=Prostate Cancer: Basic Mechanisms and Therapeutic Approaches|url=https://books.google.com/books?id=4xQAr3Uh8EUC&pg=PA11|date=1 January 2005|publisher=World Scientific|isbn=978-981-256-920-2|pages=11–}}</ref><ref name="Lehne2013" /><ref name="RamonDenis2007">{{cite book|author1=J. Ramon|author2=L.J. Denis|title=Prostate Cancer|url=https://books.google.com/books?id=Bg6ZbqhhboUC&pg=PA229|date=5 June 2007|publisher=Springer Science & Business Media|isbn=978-3-540-40901-4|pages=229–}}</ref> The incidence of interstitial pneumonitis with nilutamide has been found to be much higher in [[Japanese people|Japanese]] patients (12.6%), warranting particular caution in [[Asian people|Asian]] individuals.<ref name="Mahler1996">{{cite journal|last1=Mahler|first1=Charles|title=A Review of the Clinical Studies with Nilutamide|year=1996|pages=105–111|doi=10.1007/978-3-642-45745-6_10|quote=Akaza had to prematurely terminate a nilutamide study in Japan as 12.6% of his patients developed interstitial lung disease [4]. This complication has been mainly observed in Japan and much less in other trials worldwide.}}</ref><ref name="Micromedex2003">{{cite book|author=Micromedex|title=USP DI 2003: Drug Information for Healthcare Professionals|url=https://books.google.com/books?id=zEzWtsVl-KgC|date=1 January 2003|publisher=Thomson Micromedex|isbn=978-1-56363-429-1|pages=220–224}}</ref> There is a case report of simultaneous liver and lung toxicity in a nilutamide-treated patient.<ref name="pmid1580304">{{cite journal | vauthors = Gomez JL, Dupont A, Cusan L, Tremblay M, Tremblay M, Labrie F | title = Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report | journal = Am. J. Med. | volume = 92 | issue = 5 | pages = 563–6 | year = 1992 | pmid = 1580304 | doi = 10.1016/0002-9343(92)90756-2| url = }}</ref>

There is also a risk of [[hepatoxicity]] with nilutamide, though occurrence is very rare and the risk is significantly less than with flutamide.<ref name="JordanFurr2010">{{cite book|author1=Virgil Craig Jordan|author2=B. J. A. Furr|title=Hormone Therapy in Breast and Prostate Cancer|url=https://books.google.com/books?id=dM0uvBnxiN0C&pg=PA356|date=5 February 2010|publisher=Springer Science & Business Media|isbn=978-1-59259-152-7|pages=356–}}</ref><ref name="Aronson2009">{{cite book|author=Jeffrey K. Aronson|title=Meyler's Side Effects of Endocrine and Metabolic Drugs|url=https://books.google.com/books?id=BWMeSwVwfTkC&pg=PA150|date=21 February 2009|publisher=Elsevier|isbn=978-0-08-093292-7|pages=150–}}</ref> The incidence of abnormal [[liver function tests]] (e.g., [[elevated transaminases|elevated liver enzyme]]s) is 2–3% with nilutamide, relative to 42–62% for flutamide.<ref name="Jafri2014">{{cite journal|last1=Jafri|first1=Syed-Mohammed R.|title=Bicalutamide-induced hepatotoxicity: A rare adverse effect|journal=American Journal of Case Reports|volume=15|year=2014|pages=266–270|issn=1941-5923|doi=10.12659/AJCR.890679|pmid=24967002|pmc=4068966}}</ref><ref name="CRAIGFurr2010" /> [[Fulminant hepatic failure]] has been reported for nilutamide, with fatal outcome.<ref name="CRAIGFurr2010" /><ref name="Aronson2011">{{cite book|author=J. K. Aronson|title=Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions|url=https://books.google.com/books?id=zegpAgEt3CcC&pg=PA874|year=2011|publisher=Elsevier|isbn=978-0-444-53741-6|pages=874–}}</ref><ref name="pmid8977826">{{cite journal | vauthors = Marty F, Godart D, Doermann F, Mérillon H | title = [Fatal fulminating hepatitis caused by nilutamide. A new case] | language = French | journal = Gastroenterol. Clin. Biol. | volume = 20 | issue = 8–9 | pages = 710–1 | year = 1996 | pmid = 8977826 | doi = | url = }}</ref><ref name="MerwatKabbani2008">{{cite journal|last1=Merwat|first1=Shehzad N.|last2=Kabbani|first2=Wareef|last3=Adler|first3=Douglas G.|title=Fulminant Hepatic Failure due to Nilutamide Hepatotoxicity|journal=Digestive Diseases and Sciences|volume=54|issue=4|year=2008|pages=910–913|issn=0163-2116|doi=10.1007/s10620-008-0406-8|quote=In addition, nilutamide is noted to exhibit mitochondrial toxicity by inhibiting complex I activity of the mitochondrial respiratory chain leading to the impairment of ATP formation and the biosynthesis of glutathione, thereby possibly predisposing the liver to toxicity [13].}}</ref> Similarly to flutamide, nilutamide exhibits [[mitochondria]]l [[toxicity]] in [[hepatocyte]]s by inhibiting [[Electron transport chain#Complex I|respiratory complex I]] ([[NADH:ubiquinone reductase (H+-translocating)|NADH ubiquinone oxidoreductase]]) (though not [[Electron transport chain#Mitochondrial redox carriers|respiratory complexes II, III, or IV]]) in the [[electron transport chain]], resulting in reduced [[adenosine triphosphate|ATP]] and [[glutathione]] production and thus decreased hepatocyte survival.<ref name="MerwatKabbani2008" /><ref name="pmid8035313">{{cite journal | vauthors = Berson A, Schmets L, Fisch C, Fau D, Wolf C, Fromenty B, Deschamps D, Pessayre D | title = Inhibition by nilutamide of the mitochondrial respiratory chain and ATP formation. Possible contribution to the adverse effects of this antiandrogen | journal = J. Pharmacol. Exp. Ther. | volume = 270 | issue = 1 | pages = 167–76 | year = 1994 | pmid = 8035313 | doi = | url = }}</ref><ref name="CoeJia2007">{{cite journal|last1=Coe|first1=Kevin J.|last2=Jia|first2=Yankai|last3=Ho|first3=Han Kiat|last4=Rademacher|first4=Peter|last5=Bammler|first5=Theo K.|last6=Beyer|first6=Richard P.|last7=Farin|first7=Frederico M.|last8=Woodke|first8=Libby|last9=Plymate|first9=Stephen R.|last10=Fausto|first10=Nelson|last11=Nelson|first11=Sidney D.|title=Comparison of the Cytotoxicity of the Nitroaromatic Drug Flutamide to Its Cyano Analogue in the Hepatocyte Cell Line TAMH: Evidence for Complex I Inhibition and Mitochondrial Dysfunction Using Toxicogenomic Screening|journal=Chemical Research in Toxicology|volume=20|issue=9|year=2007|pages=1277–1290|issn=0893-228X|doi=10.1021/tx7001349|pmid=17702527|pmc=2802183}}</ref> The [[nitro compound|nitro]] [[functional group|group]] of nilutamide has been theorized to be involved in both its hepatotoxicity and its [[pulmonary toxicity]].<ref name="CoeJia2007"/><ref name="BoelsterliHo2006">{{cite journal|last1=Boelsterli|first1=Urs|last2=Ho|first2=Han|last3=Zhou|first3=Shufeng|last4=Yeow Leow|first4=Koon|title=Bioactivation and Hepatotoxicity of Nitroaromatic Drugs|journal=Current Drug Metabolism|volume=7|issue=7|year=2006|pages=715–727|issn=1389-2002|doi=10.2174/138920006778520606|pmid=17073576}}</ref>

==Pharmacology==

===Antiandrogen===
Nilutamide acts as a selective [[competitive antagonist|competitive]] [[silent antagonist]] of the AR ([[IC50|IC<sub>50</sub>]] = 412 nM),<ref name="SinghGauthier2000">{{cite journal|last1=Singh|first1=Shankar|last2=Gauthier|first2=Sylvain|last3=Labrie|first3=Fernand|title=Androgen Receptor Antagonists (Antiandrogens) Structure-Activity Relationships|journal=Current Medicinal Chemistry|volume=7|issue=2|year=2000|pages=211–247|issn=0929-8673|doi=10.2174/0929867003375371|pmid=10637363}}</ref> which prevents androgens like testosterone and DHT from activating the receptor.<ref name="Denis2012-1">{{cite book|author=Louis Denis|title=Antiandrogens in Prostate Cancer: A Key to Tailored Endocrine Treatment|url=https://books.google.com/books?id=jqZDBQAAQBAJ&pg=PT194|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-45745-6|pages=194–210}}</ref> The affinity of nilutamide for the AR is 100-fold less than that of testosterone, thus necessitating the use of relatively high dosages to achieve significant effectiveness.<ref name="BenniVemer1990">{{cite book|author1=H.J.T. Coelingh Benni|author2=H.M. Vemer|title=Chronic Hyperandrogenic Anovulation|url=https://books.google.com/books?id=q6zqFrCLUoIC&pg=PA153|date=15 December 1990|publisher=CRC Press|isbn=978-1-85070-322-8|pages=153–}}</ref> Nilutamide has approximately the same affinity for the AR as [[2-hydroxyflutamide]].<ref name="FiggChau2010">{{cite book|author1=William Figg|author2=Cindy H. Chau|author3=Eric J. Small|title=Drug Management of Prostate Cancer|url=https://books.google.com/books?id=4KDrjeWA5-UC&pg=PA71|date=14 September 2010|publisher=Springer Science & Business Media|isbn=978-1-60327-829-4|pages=71–}}</ref> Similarly to 2-hydroxyflutamide, but unlike bicalutamide, nilutamide is able to weakly activate the AR at high concentrations.<ref name="FiggChau2010"/>

Like other NSAAs such as flutamide and bicalutamide, nilutamide, without concomitant GnRH analogue therapy, increases serum androgen (by two-fold in the case of testosterone), [[estrogen]], and [[prolactin]] levels due to inhibition of AR-mediated suppression of [[steroidogenesis]] via [[negative feedback]] on the [[hypothalamic-pituitary-gonadal axis]].<ref name="Denis2012-1" /> As such, though nilutamide is still effective as an antiandrogen as a monotherapy, it is given in combination with a GnRH analogue such as [[leuprorelin]] in prostate cancer to suppress androgen concentrations to castrate levels in order to attain [[maximum androgen blockade|maximal androgen blockade]] (MAB).<ref name="Denis2012-1" />

Like flutamide and bicalutamide, nilutamide is able to cross the [[blood-brain-barrier]] and has [[central nervous system|central]] antiandrogen actions.<ref name="RaynaudBonne1979">{{cite journal|last1=Raynaud|first1=Jean-Pierre|last2=Bonne|first2=Claude|last3=Bouton|first3=Marie-Madeleine|last4=Lagace|first4=Lisette|last5=Labrie|first5=Fernand|title=Action of a non-steroid anti-androgen, RU 23908, in peripheral and central tissues|journal=Journal of Steroid Biochemistry|volume=11|issue=1|year=1979|pages=93–99|issn=0022-4731|doi=10.1016/0022-4731(79)90281-4}}</ref>

===Cytochrome P450 inhibitor===
Nilutamide is known to inhibit several [[cytochrome P450]] enzymes, including [[CYP1A2]], [[CYP2C9]], and [[CYP3A4]], and can result in increased levels of medications that are [[metabolism|metabolized]] by these [[enzyme]]s.<ref name="FerrandoLevenson2010">{{cite book|author1=Stephen J. Ferrando|author2=James L. Levenson|author3=James A. Owen|title=Clinical Manual of Psychopharmacology in the Medically Ill|url=https://books.google.com/books?id=9b5NkWZ5k8wC&pg=PA256|date=20 May 2010|publisher=American Psychiatric Pub|isbn=978-1-58562-942-8|pages=256–}}</ref> It has also been found to inhibit the enzyme [[CYP17A1]] (17α-hydroxylase/17,20-lyase) ''in vitro'' and thus the [[biosynthesis]] of androgens.<ref name="HarrisColeman1993">{{cite journal|last1=Harris|first1=Martin G.|last2=Coleman|first2=Stephen G.|last3=Faulds|first3=Diana|last4=Chrisp|first4=Paul|title=Nilutamide|journal=Drugs & Aging|volume=3|issue=1|year=1993|pages=9–25|issn=1170-229X|doi=10.2165/00002512-199303010-00002|pmid=8453188}}</ref><ref name="pmid2956461">{{cite journal | vauthors = Ayub M, Levell MJ | title = Inhibition of rat testicular 17 alpha-hydroxylase and 17,20-lyase activities by anti-androgens (flutamide, hydroxyflutamide, RU23908, cyproterone acetate) in vitro | journal = J. Steroid Biochem. | volume = 28 | issue = 1 | pages = 43–7 | year = 1987 | pmid = 2956461 | doi = 10.1016/0022-4731(87)90122-1| url = }}</ref> However, nilutamide monotherapy significantly increases testosterone levels ''in vivo'', so the clinical significance of this finding is uncertain.<ref name="HarrisColeman1993" /><ref name="pmid2956461" />

==Pharmacokinetics==
Nilutamide has a [[half-life]] of 23–87 hours, with a mean of 56 hours,<ref name="CRAIGFurr2010" /> or about two days; this allows for once-daily administration.<ref name="DenisGriffiths1999" /> [[Steady state]] (plateau) levels of the drug are attained after two weeks of administration with a dosage of 150&nbsp;mg twice daily (300&nbsp;mg/day total).<ref name="Denis2012-2">{{cite book|author=Louis Denis|title=Antiandrogens in Prostate Cancer: A Key to Tailored Endocrine Treatment|url=https://books.google.com/books?id=jqZDBQAAQBAJ&pg=PT202|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-45745-6|pages=202–|quote=The plateau level of nilutamide (steady state) was obtained after about 14 days of repeated administration of the drug (150 mg b.i.d.) and did not depend upon intervals between doses.}}</ref> It is [[metabolized]] by [[CYP2C19]], with at least five [[metabolite]]s.<ref name="ChabnerLongo2010">{{cite book|author1=Bruce A. Chabner|author2=Dan L. Longo|title=Cancer Chemotherapy and Biotherapy: Principles and Practice|url=https://books.google.com/books?id=WL4arNFsQa8C&pg=PA680|date=8 November 2010|publisher=Lippincott Williams & Wilkins|isbn=978-1-60547-431-1|pages=680–}}</ref> Virtually all of the antiandrogenic activity of nilutamide comes from the parent drug (as opposed to metabolites).<ref name="MahlerVerhelst1998">{{cite journal|last1=Mahler|first1=Ch|last2=Verhelst|first2=J|last3=Denis|first3=L|title=Clinical Pharmacokinetics of the Antiandrogens and Their Efficacy in Prostate Cancer|journal=Clinical Pharmacokinetics|volume=34|issue=5|year=1998|pages=405–417|issn=0312-5963|doi=10.2165/00003088-199834050-00005|pmid=9592622}}</ref>

==History==
Nilutamide was developed by [[Roussel Uclaf|Roussel]], first introduced in 1987 (in [[Europe]])<ref name="GanellinTriggle1996" /><ref name="CRAIGFurr2010" /> and was the second NSAA to be marketed, with flutamide preceding it and bicalutamide following it in 1995.<ref name="DenisGriffiths1999" /><ref>{{cite journal | vauthors = Wellington K, Keam SJ | title = Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer | journal = Drugs | volume = 66 | issue = 6 | pages = 837–50 | year = 2006 | pmid = 16706554 | doi = 10.2165/00003495-200666060-00007 }}</ref> It was not introduced until 1996 in the [[United States]].<ref name="Pavlik2012">{{cite book|author=Edward J. Pavlik|title=Estrogens, Progestins, and Their Antagonists: Health Issues|url=https://books.google.com/books?id=LAnpBwAAQBAJ&pg=PA167|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-1-4612-4096-9|pages=167–}}</ref><ref name="BohlGao2005">{{cite journal|last1=Bohl|first1=C. E.|last2=Gao|first2=W.|last3=Miller|first3=D. D.|last4=Bell|first4=C. E.|last5=Dalton|first5=J. T.|title=Structural basis for antagonism and resistance of bicalutamide in prostate cancer|journal=Proceedings of the National Academy of Sciences|volume=102|issue=17|year=2005|pages=6201–6206|issn=0027-8424|doi=10.1073/pnas.0500381102|pmid=15833816|pmc=1087923}}</ref><ref name="AdisInsight">http://adisinsight.springer.com/drugs/800004379</ref>

==Society and culture==

===Generic name===
''Nilutamide'' is the drug's [[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]], and [[British Approved Name|BAN]].<ref name="GanellinTriggle1996" /><ref name="MortonMorton1999" />

==References==
{{Reflist|2}}


{{Androgens and antiandrogens}}
{{Androgen receptor modulators}}
{{Use dmy dates|date=April 2017}}

[[Category:Antiandrogens]]
[[Category:CYP17A1 inhibitors]]
[[Category:Disulfiram-like drugs]]
[[Category:Hepatotoxins]]
[[Category:Hormonal antineoplastic drugs]]
[[Category:Hydantoins]]
[[Category:Nitrobenzenes]]
[[Category:Progonadotropins]]
[[Category:Prostate cancer]]
[[Category:Trifluoromethyl compounds]]